Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998

Psychiatric Services

Volumn 51, Issue 5, 2000, Pages 634-638

  Citrome, Leslie ^a   Levine, Jerome ^b   Allingham, Baerbel ^b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b Nathan S Kline Inst Psychiat Res ^*

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LITHIUM; VALPROIC ACID;

ARTICLE; DRUG EFFICACY; DRUG USE; HOSPITALIZATION; HUMAN; PRESCRIPTION; SCHIZOPHRENIA;

ACETIC ACIDS; ADULT; AMINES; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; NEW YORK; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VALPROIC ACID;

EID: 0034100648     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.51.5.634     Document Type: Article

References (51)

1. Bowden CL, Brugger AM, Swann AC, et al: Efficacy of divalproeyvs lithium and placebo in the treatment of mania. JAMA 271:918-924, 1994
2. Gerner RH, Stanton A: Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? Journal of Clinical Psychopharmacology 12(suppl):578-638, 1992
3. Chou JCY: Recent advances in treatment of acute mania. Journal of Clinical Psychopharmacology 11:3-21, 1991
4. Sussman N: Background and rationale for use of anticonvulsants in psychiatry. Cleveland Clinic Journal of Medicine 65(suppl 1):87-814, 1998
5. Freeman MP, Stoll AL: Mood stabilizer combinations: a review of safety and efficacy. American Journal of Psychiatry 155:12-21, 1998
6. Fenn HH, Robinson D, Luby V, et al: Trends in pharmacotheraphy of schizoaffective and bipolar affective disorders: a 5-year naturalistic study. American Journal of Psychiatry 153:711-713, 1996
7. Citrome L, Levine J Allingham B: Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatric Quarterly 69:283-300, 1998
8. Heninger GR, Charney DS, Sternberg DE: Lithium carbonate augmentation of antidepressant treatment. Archives of General Psychiatry 40:1335-1342, 1983
9. Wassef A, Watson DJ, Morrison P, et al: Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. Journal of Clinical Psychopharmamacology 9:45-48, 1989
10. Sheard MH, Marini JL, Bridges CI, et al: The effect of lithium on impulsive agressive behavior in man. American Journal of Psychiatry 133:1409-1413, 1976
11. Luchins DL: Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacology Bulletin 20:569-571, 1984
12. Citrome L: The use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. Journal of Pharmacy Technology 11(2):55-59, 1995
13. Citrome L, Volavka J: Psychopharmacology of violence: II. beyond the acute episode. Psychiatric Annals 27:696-703, 1997
14. Chouinard G, Beauclair L, Belanger MC: Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders (ltr). Canadian Journal of Psychiatry 43:305, 1998
15. Citrome L, Levine J, Allingham B: Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacology Bulletin 32:321-326, 1996
16. Levine J, Citrome L, Allingham B: An effectiveness study comparing oral and depot neuroleptic medications. Psychopharmacology Bulletin 33:476, 1997
17. Wassef AA, Dott SG, Harris A, et al: Critical review of GABA-ergic drugs in the treatment of schizophrenia. Journal of Clinical Psychopharmacology 19:222-232, 1999
18. Wilcox J: Divalproex sodium in the treatment of agressive behavior. Annals of Clinical Psychiatry 6:17-20, 1994
19. Nagao T, Ohshimo T, Mitsunobu K, et al: Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biological Psychiatry 14:509-523, 1979
20. Gundurewa V, Beckmann H, Zimmer R, et al: Effect of valproic acid on schizophrenic syndromes [German]. Arzneimittel-Forschung 30:1212-1213, 1980
21. Bourguignon A, Monfort JC, de Medeiros P, et al: Treatment of several psychotic states with the combination of valproic acid with diazepam [French]. Annales Ḿdico-Psychologiques 142:1214-1218, 1984
22. Altamura AC, Basile R, Mauri M, et al: Valpromide (Depamide) in the treatment of acute psychotic states: open clinical study [French]. Acta Psychiatrica Belgica 86:297-304, 1986
23. Morinigo A, Martin J, Gonzalez S, et al: Treatment of resistant schizophrenia with valproate and neuroleptic drugs. Hillside Journal of Clinical Psychiatry 11:199-207, 1989
24. Chong SA, Tan CH, Lee EL, et al: Augmentation of risperidone with valproic acid. Journal of Clinical Psychiatry 59:430, 1998
25. Linnoila M, Viukari M, Hietala O: Effect of sodium valproate on tardive dyskinesia. British Journal of Psychiatry 129:114-119, 1976
26. Dose M, Hellweg R, Yassouridis A, et al: Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 31(4):122-125, 1998
27. Ko GN, Korpi ERE, Freed WJ, et al: Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenia patients. Biological Psychiatry 20:209-215, 1985
28. McElroy SL, Keck PE, Pope HG: Sodium valproate: its use in primary psychiatric disorders. Journal of Clinical Psychopharmacology 7(1):16-24, 1987
29. Lautin A, Angrist B, Stanley M, et al: Sodium valproate in schizophrenia: some biochemical correlates. British Journal of Psychiatry 137:240-244, 1980
30. Frances A, Docherty JP, Kahn DA: The export consensus guideline series: treatment of schizophrenia. Journal of Clinical Psychiatry 57(suppl 12B):1-58, 1996
31. Collins PJ, Larkin EP, Shubsachs AP: Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatrica Scandinavica 84:150-154, 1991
32. Wilson WH: Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. Psychopharmacology 111:359-366, 1993
33. Yassa R, Dupont D: Carbamazepine in the treatment of agressive behavior in schizophrenic patients: a case report. Canadian Journal of Psychiatry 28:566-568, 1983
34. Hakola HPA, Laulumaa VA: Carbamazepine in treatment of violent schizophrenics (ltr). Lancet 1:1358, 1982
35. Neppe VM: Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. Journal of Clinical Psychiatry 44:326-331, 1983
36. Dose M, Apelt S, Emrich HM: Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Research 22:303-310, 1987
37. Okuma T, Yamashita I, Takahashi R, et al: A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatrica Scandinavica 80:250-259, 1989
38. Giakas WJ, Seibyl JP, Mazure CM: Valproate in th treatment of temper outbursts (ltr). Journal of Clinical Psychiatry 51:525, 1990
39. Mattes JA: Valproic acid for nonaffective aggression in the mentally retarded. Journal of Nervous and Mental Disease 180:601-602, 1992
40. Mazure CM, Druss BG, Cellar JS: Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol. Journal of the American Geriatrics Society 40:914-916, 1992
41. Mellow AM, Solano-Lopez C, Davis S: Sodium valproate in the treatment of behavioral disturbance in dementia. Journal of Geriatric Psychiatry and Neurology 6:205-209, 1993
42. Geracioti TD Jr: Valproic acid treatment of episodic explosiveness related to brain injury (ltr). Journal of Clinical Psychiatry 55: 416-417, 1994
43. Horne M, Lindley SE: Divalproex sodium in the treatment of agressive behavior and dysphoria in patients with organic brain syndromes (ltr). Journal of Clinical Psychiatry 56:430-431, 1995
44. Lott AD, McElroy SL, Keys MA: Valproate in the treatment of behavioral agitation in elderly patients with dementia. Journal of Neuropsychiatry and Clinical Neurosciences 7:314-319, 1995
45. Hollander E, Grossman R, Stein DJ, et al: Borderline personality disorder and impulsive-aggression: the role for divalproex sodium treatment. Psychiatric Annals 26(suppl):S464-S469, 1996
46. Donovan SJ, Susser ES, Nunes EV, et al: Divalproex treatment of disruptive adolescents: a report of ten cases. Journal of Clinical Psychiatry 58:12-15, 1997
47. Wroblewski BA, Joseph AB, Kupfer J, et al: Effectiveness fo valproic acid on destructive and aggressive behaviors in patients with acquired brain injury. Brain Injury 11:37-47, 1997
48. Kavoussi RJ, Coccaro EF: Divalproex sodium for impulsive agressive behavior in patients with personality disorder. Journal of Clinical Psychiatry 59:676-680, 1998
49. Schaffer CB, Schaffer LC: Gabapentin in the treatment of bipolar disorder (ltr). American Journal of Psychiatry 154:291-292, 1997
50. Ryback R, Ryback L: Gabapentin for behavioral dyscontrol (ltr). American Journal of Psychiatry 152:1399, 1995
51. Williams CL, Johnstone BM, Kesterson JG, et al: Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Medical Care 37:AS81-AS86, 1999